(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 37.5% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Zymeworks's revenue in 2026 is $81,263,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $21,676,165,427, with the lowest ZYME revenue forecast at $6,702,129,562, and the highest ZYME revenue forecast at $28,732,383,812. On average, 13 Wall Street analysts forecast ZYME's revenue for 2027 to be $14,463,677,692, with the lowest ZYME revenue forecast at $6,011,258,382, and the highest ZYME revenue forecast at $26,016,656,173.
In 2028, ZYME is forecast to generate $15,426,851,867 in revenue, with the lowest revenue forecast at $8,484,549,458 and the highest revenue forecast at $23,232,286,857.